Literature DB >> 16432019

Biological, antigenic and phylogenetic characterization of the flavivirus Alfuy.

Fiona J May1, Mario Lobigs, Eva Lee, Debra J Gendle, John S Mackenzie, Annette K Broom, James V Conlan, Roy A Hall.   

Abstract

Alfuy virus (ALFV) is classified as a subtype of the flavivirus Murray Valley encephalitis virus (MVEV); however, despite preliminary reports of antigenic and ecological similarities with MVEV, ALFV has not been associated with human disease. Here, it was shown that ALFV is at least 10(4)-fold less neuroinvasive than MVEV after peripheral inoculation of 3-week-old Swiss outbred mice, but ALFV demonstrates similar neurovirulence. In addition, it was shown that ALFV is partially attenuated in mice that are deficient in alpha/beta interferon responses, in contrast to MVEV which is uniformly lethal in these mice. To assess the antigenic relationship between these viruses, a panel of monoclonal antibodies was tested for the ability to bind to ALFV and MVEV in ELISA. Although the majority of monoclonal antibodies recognized both viruses, confirming their antigenic similarity, several discriminating antibodies were identified. Finally, the entire genome of the prototype strain of ALFV (MRM3929) was sequenced and phylogenetically analysed. Nucleotide (73 %) and amino acid sequence (83 %) identity between ALFV and MVEV confirmed previous reports of their close relationship. Several nucleotide and amino acid deletions and/or substitutions with putative functional significance were identified in ALFV, including the abolition of a conserved glycosylation site in the envelope protein and the deletion of the terminal dinucleotide 5'-CU(OH)-3' found in all other members of the genus. These findings confirm previous reports that ALFV is closely related to MVEV, but also highlights significant antigenic, genetic and phenotypic divergence from MVEV. Accordingly, the data suggest that ALFV is a distinct species within the serogroup Japanese encephalitis virus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432019     DOI: 10.1099/vir.0.81252-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  13 in total

Review 1.  Flavivirus Envelope Protein Glycosylation: Impacts on Viral Infection and Pathogenesis.

Authors:  Derek L Carbaugh; Helen M Lazear
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

2.  Genetic and phenotypic differences between isolates of Murray Valley encephalitis virus in Western Australia, 1972-2003.

Authors:  Cheryl A Johansen; Veronica Susai; Roy A Hall; John S Mackenzie; David C Clark; Fiona J May; Stéphane Hemmerter; David W Smith; Annette K Broom
Journal:  Virus Genes       Date:  2007-03-29       Impact factor: 2.332

3.  Both E protein glycans adversely affect dengue virus infectivity but are beneficial for virion release.

Authors:  Eva Lee; Sook Kwan Leang; Andrew Davidson; Mario Lobigs
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

4.  New insights into flavivirus evolution, taxonomy and biogeographic history, extended by analysis of canonical and alternative coding sequences.

Authors:  Gregory Moureau; Shelley Cook; Philippe Lemey; Antoine Nougairede; Naomi L Forrester; Maxim Khasnatinov; Remi N Charrel; Andrew E Firth; Ernest A Gould; Xavier de Lamballerie
Journal:  PLoS One       Date:  2015-02-26       Impact factor: 3.240

5.  Viral RNA intermediates as targets for detection and discovery of novel and emerging mosquito-borne viruses.

Authors:  Caitlin A O'Brien; Jody Hobson-Peters; Alice Wei Yee Yam; Agathe M G Colmant; Breeanna J McLean; Natalie A Prow; Daniel Watterson; Sonja Hall-Mendelin; David Warrilow; Mah-Lee Ng; Alexander A Khromykh; Roy A Hall
Journal:  PLoS Negl Trop Dis       Date:  2015-03-23

6.  A new species of mesonivirus from the Northern Territory, Australia.

Authors:  David Warrilow; Daniel Watterson; Roy A Hall; Steven S Davis; Richard Weir; Nina Kurucz; Peter Whelan; Richard Allcock; Sonja Hall-Mendelin; Caitlin A O'Brien; Jody Hobson-Peters
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

7.  Antigenic Characterization of New Lineage II Insect-Specific Flaviviruses in Australian Mosquitoes and Identification of Host Restriction Factors.

Authors:  Jessica J Harrison; Jody Hobson-Peters; Agathe M G Colmant; Joanna Koh; Natalee D Newton; David Warrilow; Helle Bielefeldt-Ohmann; Thisun B H Piyasena; Caitlin A O'Brien; Laura J Vet; Devina Paramitha; James R Potter; Steven S Davis; Cheryl A Johansen; Yin Xiang Setoh; Alexander A Khromykh; Roy A Hall
Journal:  mSphere       Date:  2020-06-17       Impact factor: 4.389

8.  A new insect-specific flavivirus from northern Australia suppresses replication of West Nile virus and Murray Valley encephalitis virus in co-infected mosquito cells.

Authors:  Jody Hobson-Peters; Alice Wei Yee Yam; Jennifer Wei Fei Lu; Yin Xiang Setoh; Fiona J May; Nina Kurucz; Susan Walsh; Natalie A Prow; Steven S Davis; Richard Weir; Lorna Melville; Neville Hunt; Richard I Webb; Bradley J Blitvich; Peter Whelan; Roy A Hall
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

Review 9.  Structure and functionality in flavivirus NS-proteins: perspectives for drug design.

Authors:  Michela Bollati; Karin Alvarez; René Assenberg; Cécile Baronti; Bruno Canard; Shelley Cook; Bruno Coutard; Etienne Decroly; Xavier de Lamballerie; Ernest A Gould; Gilda Grard; Jonathan M Grimes; Rolf Hilgenfeld; Anna M Jansson; Hélène Malet; Erika J Mancini; Eloise Mastrangelo; Andrea Mattevi; Mario Milani; Grégory Moureau; Johan Neyts; Raymond J Owens; Jingshan Ren; Barbara Selisko; Silvia Speroni; Holger Steuber; David I Stuart; Torsten Unge; Martino Bolognesi
Journal:  Antiviral Res       Date:  2009-11-27       Impact factor: 5.970

10.  Complete genome sequences of the prototype isolates of genotypes 2, 3, and 4 of murray valley encephalitis virus.

Authors:  David T Williams; Sinéad M Diviney; Karli J Corscadden; Beng Hooi Chua; John S Mackenzie
Journal:  Genome Announc       Date:  2014-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.